SingaporeSG
ChinaCN
MalaysiaMY
IndonesiaID
MyanmarMM_pddqnqv8.png)
Bio Reagents & Consumables
Vaccine mRNA
OVA mRNA
Overview
-
#MRNA42 does not bear any additional nucleotide modifications.
-
#MRNA41 is modified with 5-methoxyuridine (5moU) to reduce innate immune responses.
-
#MRNA40 is modified with N1-methyl-pseudouridine (N1-mψ) to reduce innate immune response.
| CATALOG NUMBER | UNIT SIZE |
| MRNA41-20 |
OVA mRNA (5moU) 20µg |
| MRNA41-100 |
OVA mRNA (5moU) 100µg |
| MRNA41-1000 |
OVA mRNA (5moU) 1mg |
| MRNA42-20 |
Unmodified OVA mRNA 20µg |
| MRNA42-100 |
Unmodified OVA mRNA 100µg |
| MRNA42-1000 |
Unmodified OVA mRNA 1 mg |
| MRNA40-20 |
OVA mRNA (N1-mψ) 20µg |
| MRNA40-100 |
OVA mRNA (N1-mψ) 100µg |
| MRNA40-1000 |
OVA mRNA (N1-mψ) 1 mg |
Applications
OVA mRNA encodes for OVA protein, a commonly used antigen for immunization and biochemical studies and also an established model allergen for airway hyper-responsiveness.
We offer modified OVA mRNA (5moU) and unmodified OVA mRNAs, produced by in vitro transcription and stabilized at the 5’ end by modified nucleotides capping (Cap1). They contain a poly(A) tail at the 3’ end.
- Exogenous unmodified mRNAs activate the innate immune system and cytokines production in order to influence induced immune response.
- Modified mRNAs (5moU- ref# MRNA41) are modified with 5-methoxyuridine. This nucleoside modification enhances stability and translational capacity of mRNA while diminishing its immunogenicity in vivo.
References:
- Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification - PMID: 30195789
- Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability - PMID: 18797453
| Technical Resources | Kindly refer to the "Downloads" tab. |
